melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, systemic POMC therapy suppresses melanoma growth via induction of melanogenic differentiation and angiogenesis blockade, thereby demonstrating its potential as a novel treatment modality for melanoma.
|
21126174 |
2011 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
αMSH peptide sequences, evaluated for conjugation to the PEG-Cy5-C' dot nanoparticles, bound to MC1-R with high affinity and targeted melanoma in syngenetic and xenografted melanoma mouse models.
|
29058865 |
2018 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alpha-MSH, a proopiomelanocortin (POMC)-derived peptide, is known to be produced in the pituitary, the skin, and melanoma tumors and to possess many biological effects, mainly on melanocyte pigmentation and growth.
|
9572472 |
1998 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Syndecan-2 expression was enhanced by fibroblast growth factor-2, which is known to stimulate melanoma cell migration; however, alpha-melanocyte-stimulating hormone decreased syndecan-2 expression and melanoma cell migration and invasion in a melanin synthesis-independent manner.
|
19641225 |
2009 |
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This melanogenic function of UVRAG is controlled by the melanocyte-specific transcription factor MITF as a downstream effector of the α-melanocyte-stimulating hormone (α-MSH)-cAMP signaling in the suntan response, which is compromised in BRAF mutant melanoma.
|
30209981 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Radiolabeled α-melanocyte-stimulating hormone (α-MSH) derivatives have a high potential for diagnosis and treatment of melanoma, because of high specificity and binding affinity to the melanocortin-1 receptor (MC1R).
|
30912594 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, these results indicate that HDGF downregulation participates in POMC-induced suppression of metastasis and EMT in melanoma.
|
23468531 |
2013 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Radionuclide Targeting: α-Melanocyte-stimulating hormone (α-MSH) is the most prominent peptide for targeting of melanoma tumors via the G protein-coupled melanocortin-1 receptor that is (over-)expressed by melanoma cells and melanocytes.
|
28578648 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Herein, we sought to establish a simple preparation method for an <sup>18</sup>F-labeled α-MSH analog using Al<sup>18</sup>F, and we examined its potential for the early detection of melanoma.
|
31297699 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Wnt/β-catenin signaling is stimulated by α-melanocyte-stimulating hormone in melanoma and melanocyte cells: implication in cell differentiation.
|
21040502 |
2011 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The human melanocortin-1 (MC1) receptor was stably expressed in the amelanotic mouse melanoma cell clone B16-G4F which does not express its own (mouse) MC1 receptor and hence is unresponsive to alpha melanocyte stimulating hormone (alpha MSH).
|
8856498 |
1996 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An (18)F-labeled linear alpha-MSH peptide ((18)F-FB-Ac-Nle-Asp-His-d-Phe-Arg-Trp-Gly-Lys-NH(2) [NAPamide]) shows promising melanoma imaging properties but with only moderate tumor uptake and retention.
|
19837749 |
2009 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In melanocytes and melanoma cells alpha-melanocyte stimulating hormone (alpha-MSH), via the cAMP pathway, elicits a large array of biological responses that control melanocyte differentiation and influence melanoma development or susceptibility.
|
15983061 |
2005 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Linking αMSH with PPARγ in B16-F10 melanoma.
|
22863076 |
2013 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our previous studies have indicated that POMC gene delivery inhibited the progression and metastasis of B16-F10 melanoma via the α- melanocyte-stimulating hormone/melanortin-1 receptor (MC-1R) pathway.
|
22147647 |
2012 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast to melanoma cells, nevus cells in serum-free medium require the presence of alpha-melanocyte-stimulating hormone, which enhanced intracellular levels of cyclic adenosine monophosphate.
|
8440904 |
1993 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, melanoma cells synthesize and release alpha-melanocyte stimulating hormone (alphaMSH, the ligand for MC1R), therefore MC1R variants could alter the autocrine effects of alphaMSH on melanoma cell behaviour, thereby affecting early melanoma development and progression via non-pigmentary mechanisms.
|
12439754 |
2002 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we aim to design and evaluate αMSH derivatives that enable radiolabeling with <sup>18</sup>F for PET imaging of melanoma.
|
29714486 |
2018 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
[Leu<sup>3</sup>, Leu<sup>7</sup>, Phe<sup>8</sup>]-γ-MSH-NH<sub>2</sub> is ideal for inducing short-term skin pigmentation without sun for melanoma prevention.
|
29094944 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results highlight the potential of using radiolabeled αMSH analogues in clinical applications for molecular imaging and radionuclide therapy of melanoma.
|
29182034 |
2018 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The importance of the MC1R in reducing UV-induced genotoxicity in melanocytes led us to design small peptide analogs of the physiological MC1R agonist α-melanocortin (α-melanocyte stimulating hormone; α-MSH) for the goal of utilizing them for melanoma chemoprevention.
|
25017567 |
2014 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Linear and cyclic analogues of the α-melanocyte stimulating hormone (α-MSH) targeting the human melanocortin receptor 1 (MC1R) are of pharmacological interest for detecting and treating melanoma.
|
28714883 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Radiolabeled linear or cyclic analogs of α-MSH have a great potential as diagnostic or therapeutic tools for the management of malignant melanoma.
|
28491052 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We previously identified the αMSH/Peroxisome Proliferator Activated Receptor (PPARγ) pathway as a new pathway on the B16-F10 mouse melanoma cell line.
|
29020973 |
2017 |
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MC1R, a G-protein coupled receptor with high affinity for alpha-melanocyte stimulating hormone (αMSH), modulates pigment production in melanocytes from many species and is associated with human melanoma risk.
|
29316344 |
2018 |